Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-570/coif). J.Z. serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. J.Z. reports the work was funded by the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program, and the MD Anderson Lung Cancer Moon Shot Program; and he received consulting fees from Johnson and Johnson, AstraZeneca, Novartis; payment or honoraria from Novartis, Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent, and Hengrui; other services from Novartis, Johnson and Johnson, Merck; and participation on Novartis, AstraZeneca, GenePlus, Catalyst, outside the submitted work. The other author has no conflicts of interest to declare.